Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort
| Autor: | Kelly Suchman, Yuying Luo, Ari Grinspan |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Aged 80 and over Male Biological Products Adolescent Clostridioides difficile Physiology Gastroenterology Fecal Microbiota Transplantation Middle Aged Inflammatory Bowel Diseases Immunocompromised Host Young Adult Treatment Outcome Recurrence Clostridium Infections Humans Female Neoplasm Recurrence Local Child Immunosuppressive Agents Aged Follow-Up Studies Retrospective Studies |
| Zdroj: | Digestive Diseases and Sciences. 67:4866-4873 |
| ISSN: | 1573-2568 0163-2116 |
| Popis: | Immunocompromised patients are particularly vulnerable to Clostridioides difficile infection (CDI), hospitalizations and recurrences. Studies have shown that fecal microbiota transplant (FMT) is safe and effective in immunocompromised patients.To examine the outcomes of FMT for CDI in a diverse cohort of immunocompromised patients stratified by medication class.We performed a retrospective, long-term follow-up study of FMT in immunocompromised patients, including those undergoing chemotherapy, with inflammatory bowel disease (IBD) on immunomodulators, prior solid organ transplant on immunosuppressants, on chronic steroids 20 mg/day or higher for a minimum of three months, or HIV positive. Primary outcomes included adjusted primary cure rate within 8 weeks, as well as rates of non-response, recurrences, relapses and adverse events. Secondary outcomes included adjusted overall cure rate. Primary cure rate was defined as patients not requiring repeat CDI treatment within 8 weeks after index FMT, and overall cure rate was defined as resolution of CDI symptoms after index FMT or second FMT.Our cohort included 77 immunosuppressed patients (53.2% female, median age 39.1 years, range 7-95 years). The majority of our cohort were IBD patients on biologics (62.3%). Adjusting for colectomies and deaths, our primary and overall cure rates were 85.1% and 86.5%, respectively. Twelve patients received FMT for severe or fulminant CDI with a 3-month survival rate of 91.7%. 11.7% of patients experienced serious adverse events following FMT.Our study supports the efficacy and safety of FMT in immunocompromised patients, though future research is needed to further ascertain the potential effects of immunosuppression on FMT outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink